MA52886A - Composés de purinone et leur utilisation dans le traitement du cancer - Google Patents

Composés de purinone et leur utilisation dans le traitement du cancer

Info

Publication number
MA52886A
MA52886A MA052886A MA52886A MA52886A MA 52886 A MA52886 A MA 52886A MA 052886 A MA052886 A MA 052886A MA 52886 A MA52886 A MA 52886A MA 52886 A MA52886 A MA 52886A
Authority
MA
Morocco
Prior art keywords
cancer treatment
purinone
compounds
purinone compounds
cancer
Prior art date
Application number
MA052886A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Frederick Woolf Goldberg
Martin Richard Howard
Attilla Kuan Tsuei Ting
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of MA52886A publication Critical patent/MA52886A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052886A 2018-06-15 2019-06-14 Composés de purinone et leur utilisation dans le traitement du cancer MA52886A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
MA52886A true MA52886A (fr) 2021-04-21

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052886A MA52886A (fr) 2018-06-15 2019-06-14 Composés de purinone et leur utilisation dans le traitement du cancer

Country Status (29)

Country Link
US (2) US11884671B2 (fr)
EP (1) EP3807278B1 (fr)
JP (1) JP7472044B2 (fr)
KR (1) KR20210020944A (fr)
CN (1) CN112236431B (fr)
AR (1) AR114971A1 (fr)
AU (1) AU2019287295B2 (fr)
BR (1) BR112020025127A2 (fr)
CA (1) CA3102195A1 (fr)
CL (1) CL2020003131A1 (fr)
CO (1) CO2020015758A2 (fr)
CR (1) CR20200620A (fr)
DO (1) DOP2020000241A (fr)
EA (1) EA202190006A1 (fr)
EC (1) ECSP20080276A (fr)
ES (1) ES2931448T3 (fr)
IL (1) IL279370A (fr)
JO (1) JOP20200315A1 (fr)
MA (1) MA52886A (fr)
MX (1) MX2020013570A (fr)
NI (1) NI202000099A (fr)
PE (1) PE20210003A1 (fr)
PH (1) PH12020552148A1 (fr)
SG (1) SG11202012035WA (fr)
TW (1) TWI820146B (fr)
UA (1) UA126837C2 (fr)
UY (1) UY38263A (fr)
WO (1) WO2019238929A1 (fr)
ZA (1) ZA202100195B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
JP7383818B2 (ja) * 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物
CN113121573A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN113121574B (zh) * 2019-12-31 2023-02-17 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
WO2021204111A1 (fr) * 2020-04-10 2021-10-14 南京明德新药研发有限公司 Composé d'aminopyrimidine utile en tant qu'inhibiteur de l'adn-pk et ses dérivés
EP4137491A4 (fr) 2020-04-17 2024-05-08 Chengdu Baiyu Pharmaceutical Co Ltd Dérivé d'imidazolinone et son utilisation en médecine
WO2021260583A1 (fr) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk
CN116406272A (zh) * 2020-07-20 2023-07-07 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2022135360A1 (fr) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 Dérivé de purinone, son procédé de préparation et son utilisation en médecine
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
WO2022135555A1 (fr) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 Composé de purinone, son procédé de préparation et son application pharmaceutique
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
WO2023274310A1 (fr) * 2021-06-29 2023-01-05 成都百裕制药股份有限公司 Forme cristalline de dérivés de purine et leurs compositions pharmaceutiques
CN117940437A (zh) * 2021-09-07 2024-04-26 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536841A (ja) 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
WO2010118207A1 (fr) * 2009-04-09 2010-10-14 Schering Corporation Dérivés pyrazolo[1, 5-a]pyrimidine en tant qu'inhibiteurs de mtor
EP2493895B1 (fr) 2009-10-29 2017-04-26 Vectura Limited Dérivés d'hétéroaryle contenant de l'azote en tant qu'inhibiteurs jak3
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
AP2013007158A0 (en) * 2011-03-11 2013-10-31 Gilead Calistoga Llc Combination therapies for hematologic malignancies
EP2527344A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
MY183036A (en) * 2016-12-20 2021-02-08 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer

Also Published As

Publication number Publication date
UY38263A (es) 2019-12-31
ZA202100195B (en) 2022-08-31
NI202000099A (es) 2021-09-24
BR112020025127A2 (pt) 2021-03-23
JP7472044B2 (ja) 2024-04-22
PE20210003A1 (es) 2021-01-05
CL2020003131A1 (es) 2021-04-30
ECSP20080276A (es) 2021-01-29
EP3807278B1 (fr) 2022-08-31
MX2020013570A (es) 2021-05-27
EP3807278A1 (fr) 2021-04-21
WO2019238929A1 (fr) 2019-12-19
CO2020015758A2 (es) 2021-04-30
CA3102195A1 (fr) 2019-12-19
AR114971A1 (es) 2020-11-11
SG11202012035WA (en) 2021-01-28
AU2019287295B2 (en) 2022-05-26
IL279370A (en) 2021-01-31
CR20200620A (es) 2021-03-09
TWI820146B (zh) 2023-11-01
UA126837C2 (uk) 2023-02-08
KR20210020944A (ko) 2021-02-24
US20210171525A1 (en) 2021-06-10
TW202035410A (zh) 2020-10-01
US20240150355A1 (en) 2024-05-09
CN112236431A (zh) 2021-01-15
EA202190006A1 (ru) 2021-03-29
CN112236431B (zh) 2024-02-13
PH12020552148A1 (en) 2021-07-05
DOP2020000241A (es) 2021-04-30
JP2021527095A (ja) 2021-10-11
US11884671B2 (en) 2024-01-30
AU2019287295A1 (en) 2021-02-04
JOP20200315A1 (ar) 2020-12-07
ES2931448T3 (es) 2022-12-29

Similar Documents

Publication Publication Date Title
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA43163A (fr) Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
MA45550A (fr) Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA52575A (fr) Pansement pour le traitement de la peau endommagée
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
MA47452A (fr) Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
MA47458A (fr) Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
MA41316A (fr) Gènes de détermination du sexe et leur utilisation en reproduction
MA49884A (fr) Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA47613A (fr) Compositions et procédés de traitement du cancer
MA46085A (fr) Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires
MA56392A (fr) Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies
MA54456A (fr) Composés et leur utilisation dans le traitement d'une déficience en ?1-antitrypsine
MA47408A (fr) Traitement du cancer
MA49248A (fr) Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome
MA47811A (fr) Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer